Filana Therapeutics, Inc. (FLNA) stock price, financials & research

Regular session · ET · Market data may be delayed.

Company profile

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Richard Jon Barry
Listed since: Jul 14, 2000
Employees: 19

Market position

Day range

Current $0.8201

$0.802$0.847

52-week range

Current $0.8201

$0.80$4.98

Open: $0.82
Previous close: $0.8283
Volume: 285.23K; 0.82× average
Average volume: 349.51K; Average daily volume
Market cap: 39.62M USD
Beta: -0.69; Market reference 1
50-day average: $1.0074; -18.59% below average
200-day average: $1.7215; -52.36% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 3.51M USD
P/E (TTM): -0.94×
P/B (TTM): 0.62×
P/S (TTM): 0×
EV / EBITDA: -0.04×
Earnings yield: -91.88%
Free cash flow yield: -33.16%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%
Return on equity: -122.27%
Return on assets: -76.86%
Return on invested capital: -128.00%

Financial health

Debt / equity: 0×
Current ratio: 2.23×
Altman Z-score: -7.21
Piotroski F-score: 1 of 9

Financial statements

Income trends

Operating income

−95.39M USD+32.56%

Net income

−90.97M USD-273.73%

Financial statements: Income statement
Metric (USD)	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of goods sold	936K USD	—	—	—	—
Gross profit	−936K USD	—	—	—	—
Research and development	26.59M USD	69.64M USD	89.42M USD	68.03M USD	24.81M USD
Selling, general, and administrative	67.86M USD	71.81M USD	16.53M USD	11.99M USD	8.06M USD
Operating expenses	94.45M USD	141.45M USD	105.96M USD	80.02M USD	32.87M USD
Interest income	4.62M USD	8.51M USD	7.83M USD	2.78M USD	49K USD
Depreciation and amortization	936K USD	1.13M USD	1.53M USD	1.3M USD	534K USD
Operating income	−95.39M USD	−141.45M USD	−105.96M USD	−80.02M USD	−32.87M USD
Net income	−90.97M USD	−24.34M USD	−97.22M USD	−76.25M USD	−32.39M USD

Company facts updated Sep 6, 2026.

Earnings

Latest fiscal-year EPS: -1.88; FY2025
Latest fiscal-year revenue: 0 USD; FY2025
Next fiscal-year EPS consensus: -0.895; FY2026 · 2 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast

FLNA news

gurufocus.comAug 12, 2026

Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug. 1

Read source

prnewswire.comAug 12, 2026

Did Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket…

Read source

globenewswire.comJul 29, 2026

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis…

Read source